Alnylam Pharmaceuticals (ALNY) Non Operating Income (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Non Operating Income came in at -$53.6 million in Q2 2026, down 113.6% YoY from $394.4 million in Q2 2025, and down 14.16% on a QoQ basis from -$47.0 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Non Operating Income (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Non Operating Income data on file, last reported at -$53.6 million in Q2 2026.
- Quarterly Non Operating Income fell 113.6% year-over-year to -$53.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$275.1 million (down 65.6% YoY) and the FY2025 annual result came in at -$178.4 million, up 11.01% from the prior year.
- Non Operating Income eased to -$53.6 million in Q2 2026, from -$47.0 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of -$18.4 million in Q4 2022 to a low of -$147.9 million in Q3 2022.
- A 5-year average of -$56.4 million and a median of -$46.2 million in 2025 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income sank 611.34% — and 2023, when it soared 75.65%.
- Tracing ALNY's Non Operating Income over 5 years: stood at -$18.4 million in 2022, then dropped by 15.62% to -$21.3 million in 2023, then plunged by 317.23% to -$88.8 million in 2024, then jumped by 48.81% to -$45.5 million in 2025, then dropped by 17.99% to -$53.6 million in 2026.
- The last three Non Operating Income figures came in at -$53.6 million (Q2 2026), -$47.0 million (Q1 2026), and -$45.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.64 Mn |
| Mar 31, 2026 | -46.98 Mn |
| Dec 31, 2025 | -45.46 Mn |
| Sep 30, 2025 | -129.01 Mn |
| Jun 30, 2025 | -19.16 Mn |
| Mar 31, 2025 | -20.45 Mn |
| Dec 31, 2024 | -88.80 Mn |
| Sep 30, 2024 | -31.76 Mn |
| Jun 30, 2024 | -59.78 Mn |
| Mar 31, 2024 | -20.15 Mn |
| Dec 31, 2023 | -21.28 Mn |
| Sep 30, 2023 | -63.13 Mn |
| Jun 30, 2023 | -44.38 Mn |
| Mar 31, 2023 | -22.56 Mn |
| Dec 31, 2022 | -18.41 Mn |
| Sep 30, 2022 | -147.90 Mn |
| Jun 30, 2022 | -82.99 Mn |
| Mar 31, 2022 | -92.62 Mn |
| Dec 31, 2021 | -65.74 Mn |
| Sep 30, 2021 | -22.56 Mn |